Seroatlas · Human Serome Atlas

CHRNA9

Neuronal acetylcholine receptor subunit alpha-9

Also known as: ACHA9_HUMAN, NACHRA9

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9UGM1
Gene: CHRNA9
Ensembl: ENSG00000174343
Chromosome: 4
Canonical length: 479 aa
Protein class: FDA approved drug targets, Predicted membrane proteins, Transporters

OverviewNCBI Gene

This gene is a member of the ligand-gated ionic channel family and nicotinic acetylcholine receptor gene superfamily. It encodes a plasma membrane protein that forms homo- or hetero-oligomeric divalent cation channels. This protein is involved in cochlea hair cell development and is also expressed in the outer hair cells (OHCs) of the adult cochlea. [provided by RefSeq, Feb 2012]

Canonical amino-acid sequenceUniProt

479 residues, UniProt reviewed canonical sequence.

>Q9UGM1|CHRNA9
     1  MNWSHSCISF CWIYFAASRL RAAETADGKY AQKLFNDLFE DYSNALRPVE DTDKVLNVTL
    61  QITLSQIKDM DERNQILTAY LWIRQIWHDA YLTWDRDQYD GLDSIRIPSD LVWRPDIVLY
   121  NKADDESSEP VNTNVVLRYD GLITWDAPAI TKSSCVVDVT YFPFDNQQCN LTFGSWTYNG
   181  NQVDIFNALD SGDLSDFIED VEWEVHGMPA VKNVISYGCC SEPYPDVTFT LLLKRRSSFY
   241  IVNLLIPCVL ISFLAPLSFY LPAASGEKVS LGVTILLAMT VFQLMVAEIM PASENVPLIG
   301  KYYIATMALI TASTALTIMV MNIHFCGAEA RPVPHWARVV ILKYMSRVLF VYDVGESCLS
   361  PHHSRERDHL TKVYSKLPES NLKAARNKDL SRKKDMNKRL KNDLGCQGKN PQEAESYCAQ
   421  YKVLTRNIEY IAKCLKDHKA TNSKGSEWKK VAKVIDRFFM WIFFIMVFVM TILIIARAD

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CHRNA9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 4
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 0.6 nTPM

Expression across tissuesHPA

Tissue

fallopian tube: 0.6 nTPM
skin: 0.4 nTPM
thymus: 0.3 nTPM
cerebral cortex: 0.2 nTPM
cervix: 0.1 nTPM
pituitary gland: 0.1 nTPM

Single-cell type

melanocytes: 2 nCPM
endometrial ciliated cells: 1.3 nCPM
endometrial glandular cells: 1.3 nCPM
pdcs: 1.3 nCPM
respiratory ciliated cells: 1.2 nCPM
fallopian tube ciliated cells: 1.1 nCPM

Immune cell

naive CD4 T-cell: 0.2 nTPM
naive CD8 T-cell: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM

Brain region

medulla oblongata: 1 nTPM
amygdala: 0.5 nTPM
hippocampal formation: 0.3 nTPM
hypothalamus: 0.3 nTPM
white matter: 0.3 nTPM
pons: 0.2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.98
gnomAD pLI: 0
gnomAD missense Z: -0.1
DepMap mean gene effect: -0.04
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CHRNA9 as an antibody target. Whether an autoantibody or antibody against CHRNA9 could matter depends on whether native CHRNA9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CHRNA9 is annotated at the cell surface, where native CHRNA9 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CHRNA9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...